Ieq Capital LLC Sells 243 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ieq Capital LLC cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.1% during the fourth quarter, Holdings Channel reports. The fund owned 7,650 shares of the company’s stock after selling 243 shares during the period. Ieq Capital LLC’s holdings in IDEXX Laboratories were worth $3,163,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of IDXX. Assenagon Asset Management S.A. lifted its holdings in IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after buying an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd acquired a new position in IDEXX Laboratories during the 4th quarter worth $113,104,000. Vontobel Holding Ltd. lifted its holdings in IDEXX Laboratories by 90.1% during the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after buying an additional 198,404 shares in the last quarter. Worldquant Millennium Advisors LLC lifted its holdings in IDEXX Laboratories by 230.1% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock worth $55,673,000 after buying an additional 76,809 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in IDEXX Laboratories by 150.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 108,258 shares of the company’s stock worth $54,693,000 after buying an additional 65,050 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of several research reports. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Morgan Stanley cut their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $452.77 on Friday. The company has a market capitalization of $37.08 billion, a PE ratio of 42.43, a PEG ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock’s fifty day simple moving average is $431.92 and its 200 day simple moving average is $452.40.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,330 shares of company stock valued at $6,161,276. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.